Overcoming the challenges in translational development of natural killer cell therapeutics: An opinion paper

Front Oncol. 2022 Dec 2:12:1062765. doi: 10.3389/fonc.2022.1062765. eCollection 2022.

¹ Research and Development Department, NanHua Bio-medicine CO., Ltd., Changsha, China.
² Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China.

No abstract available

Keywords: biotherapeutics; cancer; chemotherapy; immunosenescence; immunotherapy; natural killer (NK) cells.